Research Article
Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis
Table 1
Baseline characteristics in patients with fulminant colitis treated with infliximab in an opened randomized controlled open-label study.
| | Active | Control | |
| Age | 47 (29–66) | 27 (15–76) | | Sex (M/F) | 8/5 | 10/3 | Ns | Tobacco (yes/no) | 0/13 | 2/11 | Ns | Duration of disease (years) | 1 (0–19) | 0.5 (0–10) | Ns | Localization of disease | 2/4/7 | 1/3/9 | Ns | Proctus/left colon/total | | | | UCDAI score | 12 (12-12) | 12 (12-12) | Ns | Treatment at inclusion | | | | 5-ASA | | | Ns | Immunosuppressive | | | Ns | Biochemistry | | | | Hemoglobin (g/dL) | 11.7 (6.8–16.1) | 12.7 (9.3–14.1) | Ns | Albumin (g/L) | 32.6 (22.1–43.9) | 32.9 (23.4–38.4) | Ns | CRP (mg/L) | 59 (6–263) | 72 (7–316) | Ns | ESR (mm/h) | 41 (15–97) | 32 (14–65) | Ns |
|
|
Continuous variables are median (min-max). Asterisk: Mann-Whitney; Pearson Chi Square or Fishers Exact Test as appropriate.
|